This article is more than 5 years old. Information may no longer be current.

Top stories in gastroenterology: FDA approves colonoscopy prep Plenvu, Hemospray for GI bleeding

Among the top stories in gastroenterology is the FDA approving Plenvu as a pre-colonoscopy cleansing preparation. New research published in the Lancet Gastroenterology & Hepatology confirmed the discovery of three distinct subtypes of eosinophilic esophagitis. Other stories include PredictImmune announcing it has received a multimillion dollar investment from the Wellcome Trust, the FDA announcing the approval of Hemospray to treat gastrointestinal bleeds, and Atlantic Healthcare completing enrollment for a phase 3 trial for a potential treatment for pouchitis.

FDA approves low-volume colonoscopy prep Plenvu

The FDA has approved Plenvu as a pre-colonoscopy cleansing preparation, according to a press release from Salix Pharmaceuticals. Read More.

3 subtypes of EoE discovered

Eosinophilic esophagitis has three distinct subtypes associated with different clinical features and molecular pathways, according to new research published in the Lancet Gastroenterology & Hepatology. Read More.

New trial to evaluate Crohn’s biomarker test for disease prognosis

PredictImmune announced that it has received a 4.3 million British pound investment from the Wellcome Trust. The company will use the investment to study its test for prognosing Crohn’s disease. Read More.

FDA approves Hemospray device to treat GI bleeding

The FDA announced it has approved Hemospray, an endoscopic hemostat used to treat gastrointestinal bleeds. Read More.

Phase 3 trial to test potential pouchitis therapy

Atlantic Healthcare has completed enrollment for a phase 3 trial of the efficacy and safety of alicaforsen, a potential treatment for pouchitis in patients with inflammatory bowel disease. Read More.